Common Variable Immunodeficiency (CVID) Cell Models for Research

Common Variable Immunodeficiency (CVID) is the most common symptomatic primary immunodeficiency, with an estimated prevalence of 1 in 25,000 to 1 in 50,000 worldwide (WHO). It is characterized by low levels of serum immunoglobulins, impaired antibody responses, and increased susceptibility to recurrent infections, autoimmune disorders, and malignancies. The clinical phenotype is highly variable, with onset typically in adulthood (20-40 years). According to NCI, CVID patients have a significantly increased risk of lymphoma, particularly non-Hodgkin lymphoma, with a standardized incidence ratio of 8-10. The 5-year survival for CVID patients is approximately 70-80%, largely dependent on the management of complications such as chronic lung disease and lymphoma.

CVID serves as an excellent model for studying B-cell differentiation, antibody production, and immune tolerance. The disease encompasses a spectrum of genetic defects, with monogenic causes identified in only about 10-20% of cases, leaving a large proportion of patients with unknown genetic etiology. This provides a rich area for functional genomics studies to identify novel disease-causing genes. Public datasets such as the European Society for Immunodeficiencies (ESID) registry and the National Institutes of Health (NIH) CVID cohort offer extensive clinical and genetic data. Open questions include the molecular mechanisms underlying the variable penetrance and expressivity, the role of epigenetic modifications, and the interplay between genetic and environmental factors.

CVID is not a cancer itself but predisposes to malignancies, particularly lymphomas. The major pathways involved in lymphomagenesis in CVID include:

• • B-cell receptor (BCR) signaling: Defects in B-cell survival and activation lead to abnormal B-cell populations, increasing the risk of transformation.
• • NF-κB pathway: Mutations in genes such as NFKB1 and NFKB2 disrupt NF-κB signaling, which is critical for B-cell maturation and function.
• • T-cell signaling: Impaired T-cell help affects B-cell responses and may contribute to immune dysregulation.
• • DNA damage response: Defects in DNA repair mechanisms, as seen in some CVID patients, increase genomic instability and cancer risk.

Data from TCGA and COSMIC, as well as ClinVar and UniProt.

Key signaling networks deregulated in CVID include:

• • NF-κB pathway: Critical for B-cell survival and activation. Mutations in NFKB1, NFKB2, and TACI impair this pathway.
• • PI3K/AKT pathway: Involved in B-cell proliferation and survival. Aberrant activation can lead to lymphoproliferation.
• • JAK/STAT pathway: Cytokine signaling is essential for B-cell differentiation. Defects in STAT3 or STAT5B have been implicated.
• • Toll-like receptor (TLR) signaling: TLR7 and TLR9 activation is important for antibody responses; defects contribute to impaired immunity.

Organoids derived from CVID patient B-cells or iPSCs can recapitulate germinal center reactions and antibody production, providing a more physiologically relevant model for studying B-cell defects.

• • Patient-derived xenografts (PDX): Immunodeficient mice engrafted with CVID patient B-cells or lymphomas.
• • Genetically engineered mouse models (GEMM): Mice with knockouts of CVID-associated genes (e.g., Tnfrsf13b, Nfkb1) to study immune defects.
• • Induced models: Immunization or viral infection to trigger immune responses in mice with targeted mutations.

CRISPR-Cas9 gene editing enables the creation of isogenic cell lines with precise mutations in CVID-associated genes. For example, a TNFRSF13B knockout in a B-cell line (e.g., Ramos) can model TACI deficiency, while a knock-in of a specific NFKB1 mutation can mimic patient variants. These models are essential for functional validation of genetic variants and drug testing. Commercially available, sequence-verified gene-edited cell lines are available from various providers, accelerating research without the need for in-house editing.

Knockout and knock-in cell lines are used to validate the functional impact of CVID-associated genetic variants. For instance, knocking out LRBA in a B-cell line can confirm its role in autophagy and B-cell survival. Similarly, introducing a specific NFKB2 mutation can assess its effect on NF-κB signaling. These models help distinguish pathogenic variants from benign polymorphisms.

Isogenic pairs (wild-type vs. mutant) are valuable for drug screening. For example, a TACI knockout cell line can be used to test drugs that bypass TACI signaling to restore antibody production. Additionally, resistance mechanisms to immunomodulatory drugs can be studied by generating resistant cell lines through chronic exposure and then identifying genetic changes via sequencing.

CRISPR-based synthetic lethality screens can identify genes that are essential in CVID-mutant cells but not in normal cells, revealing potential therapeutic targets. For example, in NFKB1-deficient B-cells, a screen might identify kinases that compensate for the loss, which could be targeted to eliminate abnormal B-cells in lymphoma.